FDA panel recommends label change

Washington, D.C. - Responding to concerns over increased malignancies seen in animal studies, a pediatric subcommittee of the FDA's Anti-Infective Drugs Advisory Committee said topical immunosuppressant labeling should include a warning against use in children under the age of two.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.